06:44 AM EST, 03/06/2024 (MT Newswires) -- (Updates with the stock move in the headline and the first paragraph.)

Marinus Pharmaceuticals ( MRNS ) shares slumped 8% in premarket activity on Wednesday after the company reported a wider-than-anticipated loss and revenue fell shy of market expectations.

The company reported Q4 net loss late Tuesday of $0.74 per diluted share, compared with a loss of $0.76 a year earlier.

Analysts polled by Capital IQ expected a loss of $0.62.

Total revenue for the quarter ended Dec. 31 was $7.19 million, up from $7.16 million a year earlier. Analysts surveyed by Capital IQ expected $8.1 million.

Price: 8.5, Change: -0.74, Percent Change: -8.01